An observational study in 102 patients reports a 57.4% pathological complete response with CT-P6 plus pertuzumab and chemotherapy, with no signs of immunogenicity....
An analysis of the plasmaMATCH trial shows that low circulating tumor DNA levels and their disappearance during treatment are linked to better responses....
A retrospective analysis of 8,825 patients from GEICAM studies places 10-year invasive disease-free survival at 73.8% for the intermediate-risk group....
The PHERGain-2 study reaches a 59.6% pathological complete response with trastuzumab and pertuzumab without chemotherapy in selected early HER2+ patients....
The Global Burden of Disease 2023 estimates 2.30 million cases and 764,000 deaths in 2023, and forecasts a sharp rise by 2050 with wide inequalities between countries....
A qualitative study at Miguel Servet Hospital in Zaragoza identifies five themes that most shift emotions, especially side effects and waiting times....
A study in 477 patients confirms that more than 20% tumor-infiltrating lymphocytes predicts better chemotherapy response, and that their form adds information....
Genomic analysis of the SOLAR-1 trial shows that patients with FGFR1 or FGFR2 alterations or low mutational burden gain more from alpelisib plus fulvestrant....
A Spanish study of 759 breast cancer patients finds no consistent association between following cancer prevention recommendations and mammographic density....
A phase I trial with ten older or frail patients suggests that stereotactic ablative radiotherapy in five fractions, up to 40 Gy, is well tolerated and does not reach the maximum tolerated dose....
A preliminary Spanish report finds that all nine patients with severe sacituzumab govitecan toxicity carried the UGT1A1*28 allele, and advocates preventive genotyping....
The Spanish PROCURE project, with 292 patients, finds that UGT1A1 genotypes do not explain the adverse effects of trastuzumab-deruxtecan in advanced breast cancer....